Frontlight ResearchEarly access
Myeloproliferative neoplasms trials in Poland
16 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 17 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleA Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
- Where
- Gdansk, Katowice, Lublin, Skorzewo, Torun, Walbrzych, Warsaw
- Age
- 18 years and over
- People
- 460 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07357727 · EU 2025-523555-66-00 - Phase 3Not yet taking people in PolandA Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia
- Where
- Gdansk, Katowice, Krakow, Lodz, Wałbrzych, Warsaw
- Age
- 18 years and over
- People
- 426 worldwide
- Run by
- Incyte Corporation
See details and how to joinNCT07623200 · EU 2026-525398-38-00 - Phase 4Taking peopleAsciminib Roll-over Study
- Where
- Katowice, Krakow, Warsaw, Wroclaw
- Age
- 7 years to 100 years
- People
- 347 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT04877522 · EU 2023-507557-16-00 - Phase 3Not yet taking people in PolandA Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
- Where
- Chorzów, Cracow, Katowice, Lodz, Poznan, Torun, Warsaw
- Age
- 18 years and over
- People
- 324 worldwide
- Run by
- Takeda
See details and how to joinNCT07623161 · EU 2026-525660-17-00 - Phase 3Taking peopleINTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)
- Where
- Gdansk, Katowice, Lodz, Lublin, Skorzewo, Torun, Wroclaw
- Age
- 18 years and over
- People
- 250 worldwide
- Run by
- Ono Pharmaceutical Co., Ltd.
See details and how to joinNCT07429266 · EU 2025-524669-25-00 - Phase 1/2Not yet taking people in PolandA Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
- Where
- Lublin
- Age
- 18 years and over
- People
- 240 worldwide
- Run by
- Sumitomo Pharma America, Inc.
See details and how to joinNCT04176198 · EU 2022-502597-16-00 - Phase 2Active, not recruitingA Phase 2 study to evaluate the efficacy and safety of selinexor monotherapy in subjects with JAK inhibitor-naïve myelofibrosis and moderate thrombocytopenia.
- Where
- Lublin, Poznan, Torun
- Age
- 18 years and over
- People
- 38 worldwide
- Run by
- Karyopharm Therapeutics Inc.
See details and how to join2024-511309-47-00 - Phase 2Taking peopleRVU120 Rollover Study
- Where
- Chorzow, Cracow, Gdansk, Katowice, Lublin, Wroclaw
- Age
- 18 years and over
- People
- 14 worldwide
- Run by
- Ryvu Therapeutics SA
See details and how to joinNCT06987058 · EU 2025-521673-14-00 - Phase 2Active, not recruiting(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
- Where
- Lublin
- Age
- 18 years and over
- People
- 140 worldwide
- Run by
- Cogent Biosciences, Inc.
See details and how to joinNCT04996875 · EU 2024-511407-42-00 - Phase 3Taking peopleAdding Navtemadlin to Ruxolitinib for Patients with Myelofibrosis
- Where
- Białystok, Bydgoszcz, Cracow, Gdansk, Katowice, Lodz, Nowy Sacz, Olsztyn, Skorzewo, Slupsk, Szczecin, Torun, Walbrzych, Warsaw, Wroclaw
- Age
- 18 years and over
- People
- 126 worldwide
- Run by
- Kartos Therapeutics Inc.
See details and how to join2023-504724-25-00 - No phaseTaking peopleObservational Study on the Use of Ropeginterferon Alfa-2b in Polycythemia Vera (ROPEG-PV)
- Where
- Gdansk, Katowice, Krakow, Lodz, Wroclaw
- Age
- 18 years to 100 years
- People
- 429 worldwide
- Run by
- FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
See details and how to joinNCT06506084 - No phaseTaking peopleClinical Epidemiology in Contemporary Patients With Myelofibrosis.
- Where
- Krakow, Wroclaw
- Age
- 18 years to 100 years
- People
- 617 worldwide
- Run by
- FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
See details and how to joinNCT06533813 - Phase 3Active, not recruitingStudy on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera
- Where
- Poznan, Walbrzych, Wroclaw
- Age
- 18 years and over
- People
- 220 worldwide
- Run by
- Italfarmaco
See details and how to joinNCT06093672 · EU 2022-502276-23-00 - Phase 2Taking peopleA Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
- Where
- Lublin, Skorzewo, Torun
- Age
- 18 years and over
- People
- 58 worldwide
- Run by
- Karyopharm Therapeutics Inc
See details and how to joinNCT05980806 - Phase 3Taking peopleStudy of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
- Where
- Bialystok, Gdansk, Krakow, Lodz, Nowy Sącz, Olsztyn, Poznan, Słupsk, Szczecin, Wałbrzych, Warsaw, Wroclaw
- Age
- 18 years and over
- People
- 600 worldwide
- Run by
- Kartos Therapeutics, Inc.
See details and how to joinNCT06479135 - Phase 1/2Taking peopleStudy of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib
- Where
- Katowice
- Age
- 18 years and over
- People
- 70 worldwide
- Run by
- Telios Pharma, Inc.
See details and how to joinNCT05280509